Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 15,938 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 2 Clear all
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00217412
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, isotretinoin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Laparoscopic Three-dimensional Versus Two-dimensional Sacral Colpopexy and Paravaginal Repair

NCT02258230
View directory record Official record
Conditions
Pelvic Organ Prolapse, Cystocele
Interventions
3D mode of the 3D Laparoscopic Video System, 2D mode of the 3D Laparoscopic Video System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 26, 2026, 10:27 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

NCT06867107
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SAT-3247
Drug
Lead sponsor
Satellos Bioscience, Inc.
Industry
Eligibility
16 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Virtual Reality to Improve Medical Training

NCT07542834
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions
Cinematic Virtual Reality Training, Traditional Didactic Lecture
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 26, 2026, 10:27 PM EDT
Terminated Not applicable Interventional

Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis

NCT02523794
View directory record Official record
Conditions
Pelvic Pain
Interventions
Electro-kinetically Modified Water, Placebo
Other
Lead sponsor
Revalesio Corporation
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

NCT00520481
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
IMC-A12 (Cixutumumab)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 26, 2026, 10:27 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Randomized Controlled Physical Activity App Intervention for Black Women

NCT07114900
View directory record Official record
Conditions
Physical Activity
Interventions
PA4Health app physical activity intervention, Wellness Text Messaging Program
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

NCT00856492
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
365
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chicago Urban Resiliency Building (CURB)

NCT01571011
View directory record Official record
Conditions
Major Depression
Interventions
CURB
Behavioral
Lead sponsor
Benjamin Van Voorhees, MD, MPH
Other
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sitting Interruption and Whole-body Cardiovascular Health

NCT05316571
View directory record Official record
Conditions
Sedentary Behavior, Sedentary Time
Interventions
One 5-Minute Walking Bout Each Hour, One 15-Minute Standing Bout Each Hour, One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour, Uninterrupted Sitting
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02179086
View directory record Official record
Conditions
Glioblastoma
Interventions
Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
230
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 10:27 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753
View directory record Official record
Conditions
Synovial Sarcoma, Soft Tissue Sarcoma
Interventions
CFT8634
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 26, 2026, 10:27 PM EDT
Not listed Not applicable Interventional

Usability of the Adapted Rower for People With Spinal Cord Injury

NCT05959837
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Adaptive Rowing Exercise
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 26, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Complement Regulation to Undo Systemic Harm in Preeclampsia

NCT04725812
View directory record Official record
Conditions
Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP, HELLP Syndrome, HELLP Syndrome Second Trimester, Pregnancy Related, AHUS, PNH, Complement Regulatory Factor Defect, Complement Abnormality, HELLP Syndrome Third Trimester
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 26, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412
View directory record Official record
Conditions
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Interventions
HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Feasibility of Implantable Myoelectric Sensors to Control Upper Limb Prostheses

NCT01901081
View directory record Official record
Conditions
Amputation, Traumatic
Interventions
IMES
Device
Lead sponsor
The Alfred E. Mann Foundation for Scientific Research
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

A Study of BNC105P Combined With Ibrutinib

NCT03454165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
BNC105P, Ibrutinib
Combination Product
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 26, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

A Randomized Controlled Trial Comparing Sutures vs Staples for High Tension Closures

NCT06638736
View directory record Official record
Conditions
Surgery, Skin Cancer, Suture; Complications, Infection or Inflammation
Interventions
Wound Closure with sutures vs staples
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Transcranial Magnetic Stimulation for Tinnitus

NCT01104207
View directory record Official record
Conditions
Tinnitus
Interventions
repetitive transcranial magnetic stimulation (rTMS), placebo rTMS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 26, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

MultiCenter IDE Study of the PEEK-OPTIMA™ Femoral Component vs a CoCr Alloy TKA Femoral Component of Similar Design

NCT06627673
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Total Knee Arthroplasty
Device
Lead sponsor
Maxx Orthopedics Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Leawood, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

NCT01977573
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Azusa, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 26, 2026, 10:27 PM EDT